acetylsalicylic acid
Trade name: aspirin
Small moleculeapproved
Approved
Apr 12, 1950
Aspirin is a nonsteroidal anti-inflammatory drug. Aspirin is unique in this class of drugs because it irreversibly inhibits both COX-1 and COX-2 activity by acetylating a serine residue (Ser529 and Ser516, respectively) positioned in the arachidonic acid-binding channel, thus inhibiting the synthesis of prostaglandins and reducing the inflammatory response. The drug is used either alone or in combination with other compounds for the treatment of pain, headache, as well as for reducing the risk of stroke and heart attacks in patients with brain ischemia and cardiovascular diseases. — NCATS
Clinical trial activity
1,272 trials · 988 clinical orgs · 67 marketing orgs
Phase 1
170
Phase 2
458
Phase 3
318
Phase 4
403
Earliest trial started Dec 31, 1899
Timeline
1890s
- Jan 1, 1899
Bayer — Earliest Phase 1 Sponsor
- Jun 1, 1899
Evidence of US Marketing
1950s
- Apr 12, 1950
Earliest FDA Approval
- Apr 12, 1950
Endo Pharmaceuticals — Marketing Organization
- Apr 12, 1950
Endo Pharmaceuticals — NDA Secondary Org
- Nov 12, 1957
Xanodyne Pharmaceuticals — Marketing Organization
- Nov 12, 1957
Xanodyne Pharmaceuticals — NDA Secondary Org
- Jul 7, 1958
Sun Pharmaceuticals — NDA Secondary Org
1960s
- Apr 15, 1960
AH Robins — Marketing Organization
- Apr 15, 1960
AH Robins — NDA Secondary Org
- Sep 12, 1960
Meda Pharmaceuticals — Marketing Organization
- Sep 12, 1960
Meda Pharmaceuticals — NDA Secondary Org
- Mar 4, 1964
Bausch Health Companies — NDA Secondary Org
- Mar 4, 1964
Medicis — Marketing Organization
- Jun 25, 1965
Bayer — First NDA Organization
- Jun 25, 1965
Bayer — NDA Organization
1970s
- Dec 22, 1970
Sandoz — Marketing Organization
- Sep 9, 1971
AAIPharma — Marketing Organization
- Sep 9, 1971
AAIPharma — NDA Secondary Org
- Jan 1, 1974
Earliest Phase 3 Sponsor(trial)
- Sep 23, 1975
Alta Pharma — Marketing Organization
- Nov 12, 1975
Sanofi-Aventis — Marketing Organization
- Nov 12, 1975
Sanofi-Aventis — NDA Secondary Org
- May 4, 1976
Allergan — NDA Secondary Org
- May 4, 1976
Allergan — Marketing Organization
- Apr 14, 1978
Teva — Marketing Organization
- May 10, 1978
R.P. Scherer — Marketing Organization
- Jul 31, 1978
Medpointe — Marketing Organization
- Aug 21, 1978
Watson Pharmaceuticals — Marketing Organization
- Jun 5, 1979
Hikma — Marketing Organization
- Jul 25, 1979
Actavis — Marketing Organization
1980s
- Apr 30, 1980
Puracap Pharmaceutical — Marketing Organization
- Jul 30, 1980
Fosun — Marketing Organization
- Dec 28, 1981
Lannett Company, Inc. — Marketing Organization
- Jun 4, 1982
Roxane Laboratories — Marketing Organization
- Jul 1, 1982
Halsey — Marketing Organization
- Dec 14, 1983
Abbott — Marketing Organization
- Jan 1, 1985
Earliest Phase 2 Sponsor(trial)
- Feb 12, 1986
McNeil — Marketing Organization
- Feb 12, 1986
Johnson and Johnson — Marketing Organization
- Jan 25, 1988
Schwarz Pharma — Marketing Organization
- Nov 4, 1988
Par Pharmaceuticals — Marketing Organization
- Mar 31, 1989
Heritage Pharma — Marketing Organization
1990s
- Oct 26, 1990
Mikart — Marketing Organization
- Oct 26, 1990
SmithKline Beecham — NDA Secondary Org
- Jan 31, 1995
Jerome Stevens Pharmaceuticals — Marketing Organization
- Apr 16, 1996
Novartis — Marketing Organization
- Dec 10, 1997
Oxford Pharmaceuticals — Marketing Organization
- Jan 14, 1998
GlaxoSmithKline — Marketing Organization
- Jan 14, 1998
GlaxoSmithKline — NDA Secondary Org
- May 29, 1998
Galt Pharmaceuticals — Marketing Organization
- Mar 5, 1999
Vintage — Marketing Organization
- Nov 22, 1999
Boehringer Ingelheim — Marketing Organization
- Nov 22, 1999
Boehringer Ingelheim — NDA Secondary Org
2000s
- Nov 26, 2001
Perrigo — Marketing Organization
- Nov 30, 2001
Nexgen Pharma, Inc — Marketing Organization
- Nov 30, 2001
LGM Pharma — Marketing Organization
- Jun 24, 2003
Bristol-Myers Squibb — Marketing Organization
- Jun 24, 2003
Bristol-Myers Squibb — NDA Secondary Org
- Jun 13, 2007
Nostrum Laboratories — Marketing Organization
- Aug 14, 2009
Barr Laboratories — Marketing Organization
2010s
- Jan 7, 2010
Ingenus Pharmaceuticals — Marketing Organization
- Jan 7, 2010
Novast Labs — Marketing Organization
- Mar 16, 2011
Mayne Pharma — Marketing Organization
- Jan 14, 2013
PLx Pharma — NDA Secondary Org
- Sep 4, 2015
Espero BioPharma — NDA Secondary Org
- Mar 8, 2016
Amneal Pharmaceuticals — Marketing Organization
- Sep 14, 2016
Genus Oncology, LLC — Marketing Organization
- Sep 14, 2016
Genus Oncology, LLC — NDA Secondary Org
- Sep 22, 2016
Pharmaceutics International, Inc. — Marketing Organization
- Sep 22, 2016
Esteve Labs — Marketing Organization
- Sep 22, 2016
Strides Pharma Science — Marketing Organization
- Jan 18, 2017
Ani Pharmaceuticals — Marketing Organization
- Aug 29, 2017
Zydus Discovery DMCC — Marketing Organization
- Aug 21, 2018
Sun Pharmaceuticals — Marketing Organization
- Oct 10, 2018
Dr. Reddy's Laboratories — Marketing Organization
- Mar 20, 2019
Chartwell Pharmaceuticals — Marketing Organization
- May 24, 2019
Glenmark Pharmaceuticals — Marketing Organization
2020s
- Jul 16, 2020
Epic Pharma Llc — Marketing Organization
- Feb 23, 2021
Granules India — Marketing Organization
- Aug 11, 2021
Micro Labs Ltd India — Marketing Organization
- Feb 2, 2022
Aurobindo Pharma — Marketing Organization
Indications
Approved for
Studied for
- Abortion, Habitual · Phase 4
- Abortion, Spontaneous · Phase 4
- Abruptio Placentae · Phase 3
- Accidents · Phase 4
- Acupuncture · Phase 2
- Acute Chest Syndrome · Phase 3
- Acute Coronary Syndrome · Phase 4
- Acute Lung Injury · Phase 2
- Adenoma · Phase 2/Phase 3
- Adenomatous Polyps · Phase 3
- Adenomyosis · Early Phase 1
- Aggressive Periodontitis · Phase 2/Phase 3
- Aging · Phase 4
- Air Travel · Phase 2/Phase 3
- Albuminuria · Phase 4
- Allergy and Immunology · Phase 2/Phase 3
- alpha 1-Antitrypsin Deficiency · Phase 2
- Analgesia · Phase 4
- Analgesics · Phase 4
- Analgesics, Non-Narcotic · Phase 4
- Analgesics, Opioid · Phase 4
- Anemia, Sickle Cell · Phase 3
- Anesthesia · Phase 4
- Aneurysm · Phase 4
- Angina Pectoris · Phase 4
- Angina, Stable · Phase 4
- Angina, Unstable · Phase 4
- Angiogenesis Modulating Agents · Early Phase 1
- Angioplasty, Balloon, Coronary · Phase 4
- Ankle Fractures · Early Phase 1
- Anticoagulants · Phase 4
- Anti-Inflammatory Agents · Phase 4
- Anti-Inflammatory Agents, Non-Steroidal · Phase 4
- Antioxidants · Phase 3
- Antiphospholipid Syndrome · Phase 4
- Antithrombins · Phase 4
- Aorta · Phase 1
- Aortic Stenosis, Subvalvular · Phase 4
- Aortic Valve Disease · Phase 4
- Aortic Valve Insufficiency · Phase 4
- Aortic Valve Stenosis · Phase 4
- Appendix · Phase 4
- Art · Phase 3
- Arterial Occlusive Diseases · Phase 4
- Arteriosclerosis · Phase 4
- Arthritis · Phase 4
- Arthritis, Rheumatoid · Phase 4
- Arthroplasty · Phase 4
- Arthroplasty, Replacement, Hip · Phase 4
- Aspirin · Phase 4
- Asthma · Phase 3
- Asthma, Aspirin-Induced · Phase 4
- Atherosclerosis · Phase 4
- Athletic Performance · Phase 2
- Atrial Appendage · Phase 4
- Atrial Fibrillation · Phase 4
- Atrial Function, Left · Phase 3
- Barrett Esophagus · Phase 4
- Bipolar Disorder · Phase 2
- Bleeding Time · Phase 2
- Blindness · Phase 3
- Blood Platelet Disorders · Phase 4
- Blood Platelets · Phase 4
- Blood Pressure · Phase 4
- Blood Viscosity · Phase 4
- Body Fluids · Phase 4
- Body Weight · Phase 4
- Brain Death · Phase 3
- Brain Infarction · Phase 3
- Brain Injuries, Traumatic · Phase 4
- Brain Ischemia · Phase 4
- Breast Neoplasms · Phase 3
- CADASIL · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Squamous Cell · Phase 3
- Cardiomyopathy, Hypertrophic · Phase 3
- Cardiovascular Diseases · Phase 4
- Carotid Artery Diseases · Phase 4
- Carotid Artery Injuries · Early Phase 1
- Carotid Stenosis · Phase 4
- Cataract · Phase 3
- Central Nervous System Depressants · Phase 4
- Cerebral Hemorrhage · Phase 3
- Cerebral Infarction · Phase 4
- Cerebral Small Vessel Diseases · Phase 4
- Cerebrovascular Disorders · Phase 4
- Cerebrovascular Trauma · Phase 4
- Cervix Uteri · Phase 4
- Chagas Disease · Phase 4
- Chemoradiotherapy · Phase 2
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 4
- Chronic Limb-Threatening Ischemia · Phase 4
- Clopidogrel · Phase 1
- Cognition Disorders · Phase 1/Phase 2
- Cognitive Dysfunction · Phase 2
- Cold Temperature · Phase 3
- Colitis, Ulcerative · Phase 3
- Colonic Neoplasms · Phase 3
- Colonic Polyps · Phase 3
- Colorectal Neoplasms · Phase 3
- Colorectal Neoplasms, Hereditary Nonpolyposis · Phase 3
- Common Cold · Phase 4
- Constriction, Pathologic · Phase 3
- Coronary Aneurysm · Phase 3
- Coronary Angiography · Early Phase 1
- Coronary Artery Bypass · Phase 4
- Coronary Artery Bypass, Off-Pump · Phase 3
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- Coronary Restenosis · Phase 4
- Coronary Stenosis · Phase 4
- Coronary Thrombosis · Phase 4
- Coronavirus Infections · Phase 2
- Cough · Phase 1
- COVID-19 · Phase 3
- Craniocerebral Trauma · Phase 4
- Critical Illness · Phase 3
- Crohn Disease · Phase 3
- Delivery, Obstetric · Phase 3
- Dementia · Phase 4
- Dementia, Vascular · Phase 4
- Dental Caries · Phase 4
- Depression · Phase 4
- Depressive Disorder · Phase 2
- Depressive Disorder, Treatment-Resistant · Phase 4
- Dermatology · Phase 2
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 1 · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Nephropathies · Phase 4
- Diabetic Retinopathy · Phase 3
- Diet Therapy · Phase 2
- Disability Evaluation · Phase 4
- Disseminated Intravascular Coagulation · Phase 2
- Drug-Eluting Stents · Phase 4
- Drug Interactions · Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Generic · Phase 1
- Drugs, Investigational · Phase 4
- Drug Therapy · Phase 4
- Dry Eye Syndromes · Phase 2
- Dual Anti-Platelet Therapy · Phase 4
- Dyslipidemias · Phase 4
- Eclampsia · Phase 4
- Embolic Stroke · Phase 4
- Embolism · Phase 4
- Embolism and Thrombosis · Phase 2
- Embolism, Paradoxical · Phase 4
- Embryo Transfer · Phase 4
- Emphysema · Phase 2
- Endometrial Neoplasms · Phase 2
- Endometriosis · Phase 4
- Endothelial Cells · Phase 4
- Endothelium · Phase 1/Phase 2
- Endovascular Procedures · Phase 4
- Enoxaparin · Phase 4
- Epidermal Growth Factor · Phase 2
- Epilepsy · Phase 2
- Epithelial-Mesenchymal Transition · Phase 2
- Esophageal Neoplasms · Phase 3
- Essential Hypertension · Phase 4
- Exercise · Phase 2
- Fallopian Tube Diseases · Early Phase 1
- Fallopian Tube Neoplasms · Early Phase 1
- Fatigue · Phase 3
- Fatty Acids · Phase 2
- Fatty Liver · Phase 2
- Feeding and Eating Disorders · Early Phase 1
- Fertilization in Vitro · Phase 4
- Fetal Growth Retardation · Phase 4
- Fever · Phase 4
- Fibrinolysis · Phase 3
- Fibrinolytic Agents · Phase 3
- Fibrocystic Breast Disease · Phase 2
- Fibrosis · Phase 4
- Flushing · Phase 4
- Fontan Procedure · Phase 4
- Foramen Ovale, Patent · Phase 4
- Fractures, Bone · Phase 3
- Gastroesophageal Reflux · Phase 4
- Gastrointestinal Hemorrhage · Phase 4
- General Surgery · Phase 4
- Geriatrics · Phase 3
- Giant Cell Arteritis · Phase 2
- Gingivitis · Phase 2
- Glioblastoma · Phase 2
- Glucosephosphate Dehydrogenase Deficiency · Phase 4
- Gonadotropin-Releasing Hormone · Phase 4
- Hamartoma · Early Phase 1
- Headache · Phase 4
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 4
- Hearing Loss, Sensorineural · Phase 3
- Heart · Phase 4
- Heart Defects, Congenital · Phase 4
- Heart Disease Risk Factors · Phase 4
- Heart Diseases · Phase 4
- Heart Failure · Phase 4
- Heart Septal Defects, Atrial · Phase 4
- Heart Transplantation · Phase 3
- Heart Valve Diseases · Phase 4
- Heart Valves · Phase 4
- Hematology · Phase 1
- Hematoma · Phase 4
- Hematoma, Subdural, Chronic · Phase 4
- Hematuria · Phase 4
- Hemodilution · Phase 3
- Hemorrhage · Phase 4
- Hemorrhagic Disorders · Phase 4
- Heparin, Low-Molecular-Weight · Phase 3
- Herpes Simplex · Phase 1
- Hip Fractures · Phase 3
- HIV · Phase 2
- HIV Infections · Phase 2
- Hydroxymethylglutaryl-CoA Reductase Inhibitors · Phase 2
- Hypercholesterolemia · Phase 4
- Hyperlipidemias · Phase 4
- Hypertension · Phase 4
- Hypertension, Portal · Phase 4
- Hypertension, Pregnancy-Induced · Phase 4
- Hypertension, Pulmonary · Phase 2
- Hypertriglyceridemia · Phase 1
- Hypertrophy, Left Ventricular · Phase 4
- Hypothyroidism · Phase 2
- Infant, Low Birth Weight · Phase 3
- Infant, Premature, Diseases · Phase 2
- Infant, Small for Gestational Age · Phase 2
- Infant, Very Low Birth Weight · Phase 2
- Infarction, Middle Cerebral Artery · Phase 3
- Infertility · Phase 4
- Infertility, Female · Phase 4
- Inflammation · Phase 2/Phase 3
- Insulin Resistance · Phase 4
- Intermittent Claudication · Phase 4
- Intestinal Neoplasms · Phase 4
- Intracranial Aneurysm · Phase 4
- Intracranial Arteriosclerosis · Phase 4
- Intracranial Embolism · Phase 4
- Intracranial Hemorrhages · Phase 4
- Ischemia · Phase 4
- Ischemic Attack, Transient · Phase 4
- Ischemic Stroke · Phase 4
- Joint Diseases · Phase 3
- Ketamine · Phase 4
- Ketorolac · Phase 3
- Kidney Failure, Chronic · Phase 4
- Kidney Transplantation · Phase 4
- Knee · Phase 3
- Leg Ulcer · Phase 3
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Livedoid Vasculopathy · Phase 3
- Liver Neoplasms · Phase 2
- Low Back Pain · Phase 3
- Lung Diseases · Phase 3
- Lung Diseases, Obstructive · Phase 1
- Lung Neoplasms · Phase 2
- Lupus Erythematosus, Systemic · Phase 4
- Lymphoma, T-Cell · Phase 2
- Macular Degeneration · Phase 3
- Major Depressive Disorder · Phase 4
- Medication Adherence · Phase 4
- Medicine, Chinese Traditional · Phase 4
- Melanoma · Phase 2
- Menstruation Disturbances · Phase 2
- Mental Health · Phase 2/Phase 3
- Metabolic Syndrome · Phase 4
- Metabolism · Phase 4
- MINOCA · Phase 4
- Mitral Valve Annuloplasty · Phase 4
- Mitral Valve Insufficiency · Phase 4
- Mood Disorders · Phase 4
- Mouth Neoplasms · Phase 2/Phase 3
- Mucocutaneous Lymph Node Syndrome · Phase 4
- Multiple Myeloma · Phase 3
- Multiple Pulmonary Nodules · Phase 2
- Multiple Sclerosis · Phase 3
- Multiple Sclerosis, Relapsing-Remitting · Phase 4
- Muscle Spasticity · Phase 4
- Musculoskeletal Diseases · Phase 4
- Mutation · Phase 3
- Myeloproliferative Disorders · Phase 3
- Myocardial Infarction · Phase 4
- Myocardial Ischemia · Phase 4
- Myocardial Reperfusion Injury · Phase 4
- Myocardial Stunning · Phase 4
- Myocardium · Phase 4
- Nasopharyngeal Carcinoma · Phase 2
- Neointima · Early Phase 1
- Neoplasm Metastasis · Phase 4
- Neoplasms · Phase 4
- Neoplasms, Germ Cell and Embryonal · Phase 2
- Neoplastic Cells, Circulating · Phase 2
- Nerve Block · Phase 4
- Neuralgia, Postherpetic · Phase 1
- Neurofibromatosis 2 · Phase 2
- Neuroma, Acoustic · Phase 2
- Neurotransmitter Agents · Phase 4
- Nicotiana · Phase 2
- Non-alcoholic Fatty Liver Disease · Phase 1/Phase 2
- Non-ST Elevated Myocardial Infarction · Phase 4
- No-Reflow Phenomenon · Phase 4
- Obesity · Phase 4
- Obstetric Labor, Premature · Phase 3
- Obstetrics · Phase 3
- Optic Neuropathy, Ischemic · Phase 2
- Osteoarthritis · Phase 3
- Osteonecrosis · Phase 3
- Osteosarcoma · Phase 4
- Ovarian Hyperstimulation Syndrome · Phase 4
- Ovarian Neoplasms · Phase 4
- Pancreatic Neoplasms · Phase 3
- Pelvic Pain · Phase 4
- Peptic Ulcer · Phase 4
- Percutaneous Coronary Intervention · Phase 4
- Pericarditis · Phase 4
- Perinatal Death · Phase 3
- Periodontal Diseases · Phase 2
- Periodontitis · Phase 4
- Perioperative Care · Phase 4
- Peripheral Arterial Disease · Phase 4
- Peripheral Nervous System Agents · Phase 4
- Peripheral Vascular Diseases · Phase 4
- Pharmacokinetics · Phase 4
- Pharmacology · Phase 4
- Pharmacology, Clinical · Phase 1
- Pharyngitis · Phase 4
- Physiological Effects of Drugs · Phase 4
- Pigmentation · Phase 4
- Placenta Diseases · Phase 4
- Placental Insufficiency · Phase 4
- Platelet Aggregation · Phase 4
- Platelet Aggregation Inhibitors · Phase 4
- Platelet Function Tests · Phase 3
- Pneumonia · Phase 2/Phase 3
- Pneumonia, Viral · Phase 2
- Polycystic Ovary Syndrome · Phase 2
- Polycythemia Vera · Phase 3
- Polyps · Phase 2/Phase 3
- Postoperative Complications · Phase 2
- Postpartum Period · Phase 3
- Precancerous Conditions · Phase 3
- Pre-Eclampsia · Phase 4
- Pregnancy · Phase 4
- Pregnancy Complications · Phase 4
- Pregnancy, High-Risk · Phase 2
- Pregnancy, Twin · Phase 4
- Premature Birth · Phase 4
- Primary Myelofibrosis · Phase 3
- Primary Prevention · Phase 4
- Prostatic Neoplasms · Phase 4
- Prostheses and Implants · Phase 4
- Protein S Deficiency · Phase 2
- Psychotic Disorders · Phase 3
- Pulmonary Disease, Chronic Obstructive · Phase 3
- Pulmonary Embolism · Phase 4
- Purpura, Thrombocytopenic · Phase 2
- Purpura, Thrombocytopenic, Idiopathic · Phase 2
- Purpura, Thrombotic Thrombocytopenic · Phase 2/Phase 3
- Receptors, Purinergic P2Y12 · Phase 4
- Rectal Neoplasms · Phase 2
- Recurrence · Phase 3
- Renal Insufficiency · Phase 3
- Renal Insufficiency, Chronic · Phase 4
- Respiratory Distress Syndrome · Phase 2
- Respiratory Function Tests · Phase 1
- Respiratory Insufficiency · Phase 2
- Respiratory Tract Infections · Phase 4
- Retinal Artery Occlusion · Phase 3
- Retinal Vein Occlusion · Phase 3
- Rheumatic Heart Disease · Phase 3
- Rhinorrhea · Phase 1
- Risk Factors · Phase 3
- Rivaroxaban · Phase 3
- RNA · Early Phase 1
- Sarcoma · Phase 4
- Schizophrenia · Phase 3
- Scleroderma, Systemic · Phase 4
- Secondary Prevention · Phase 4
- Sensory System Agents · Phase 4
- Sepsis · Phase 2
- Signs and Symptoms · Phase 1
- Skeleton · Phase 2
- Sleep · Early Phase 1
- Sleep Disorders, Intrinsic · Early Phase 1
- Sleep Initiation and Maintenance Disorders · Early Phase 1
- Small Cell Lung Carcinoma · Phase 2
- Smoking · Early Phase 1
- Smoking Cessation · Phase 2
- Sneezing · Phase 1
- Splenectomy · Phase 4
- Staphylococcal Infections · Phase 4
- ST Elevation Myocardial Infarction · Phase 4
- Stents · Phase 4
- Stomach Neoplasms · Phase 4
- Stomach Ulcer · Phase 3
- Stress, Psychological · Phase 1/Phase 2
- Stroke, Lacunar · Phase 4
- Survival · Phase 3
- Tachycardia, Ventricular · Phase 4
- Tension-Type Headache · Phase 4
- Testicular Neoplasms · Phase 2
- Therapeutic Equivalency · Phase 1
- Therapeutics · Phase 2/Phase 3
- Thrombocythemia, Essential · Phase 3
- Thrombocytopenia · Phase 3
- Thromboembolism · Phase 4
- Thrombophilia · Phase 3
- Thrombosis · Phase 4
- Thyroiditis, Autoimmune · Phase 4
- Thyroid Neoplasms · Phase 2
- Ticagrelor · Phase 4
- T-Lymphocytes · Phase 2
- Tobacco Use Disorder · Phase 2
- Tomography, Optical Coherence · Early Phase 1
- Tonsillitis · Phase 4
- Tooth Abnormalities · Early Phase 1
- Toxemia · Phase 4
- Transcatheter Aortic Valve Replacement · Phase 4
- Traumatology · Early Phase 1
- Tuberculosis · Phase 2
- Tuberculosis, Meningeal · Phase 3
- Tuberculosis, Multidrug-Resistant · Phase 2
- Tuberculosis, Pulmonary · Phase 2
- Tuberous Sclerosis · Phase 2
- Typhoid Fever · Early Phase 1
- Ulcer · Phase 1
- Upper Extremity Deep Vein Thrombosis · Phase 4
- Urinary Bladder Neoplasms · Phase 4
- Urological Manifestations · Phase 3
- Uterine Cervical Neoplasms · Phase 2
- Uterine Diseases · Phase 2
- Uterine Neoplasms · Phase 2
- Vaccines · Early Phase 1
- Vascular Calcification · Phase 4
- Vascular Diseases · Phase 4
- Vascular Endothelial Growth Factor A · Phase 4
- Vascular Grafting · Phase 4
- Venous Cutdown · Phase 4
- Venous Thromboembolism · Phase 4
- Venous Thrombosis · Phase 4
- Ventricular Outflow Obstruction · Phase 3
- Ventricular Premature Complexes · Phase 4
- Vertebral Artery · Early Phase 1
- Vertebral Artery Dissection · Phase 3
- Visual Acuity · Phase 3
- Vitamin D Deficiency · Phase 2
- Warfarin · Phase 3
- Wounds and Injuries · Phase 4
Mechanism of action
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Combination products
aggrenox
with dipyridamole
axotal
with butalbital
codeine, aspirin, apap formula
with acetaminophen, codeine
darvon compoun
with caffeine, propoxyphene
Also known as compoun, propoxyphene compoun
darvon w/ asa
with propoxyphene
Also known as darvon-n w/ asa
equagesic
with meprobamate
Also known as mepro-aspirin, micrainin
excedrin (migraine relief)
with acetaminophen, caffeine
fiorinal
with caffeine, butalbital
Also known as lanorinal
fiorinal w/codeine
with caffeine, codeine, butalbital
norgesic forte
with caffeine, orphenadrine hydrochloride
Also known as invagesic, invagesic forte, norgesic, orphengesic, orphengesic forte
percodan-demi
with oxycodone
Also known as codoxy, oxycodone and aspirin, oxycodone and aspirin (half-strength), percodan, roxiprin
pravigard pac (copackaged)
with pravastatin
robaxisal
with methocarbamol
soma compoun
with carisoprodol
soma compound w/ codeine
with carisoprodol, codeine
synalgos-dc
with caffeine, dihydrocodeine
talwin compoun
with pentazocine
vicoprin
with hydrocodone
Also known as azdone
yosprala
with omeprazole
Approval history
- approvedApr 12, 1950
- approvedJun 1, 1899
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)Oc1ccccc1C(=O)O- Mol. weight
- 180.16 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Over the Counter
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL25 ↗
- WikipediaAcetylsalicylic acid/dipyridamole ↗
- NCATSR16CO5Y76E ↗
- ChEMBLCHEMBL2103751 ↗
- WikipediaAspirin ↗
- NCATSXAN4V337CI ↗
Also known as
- 1,2,3-propanetricarboxylate, 2-hydroxy-, mixt. with 2-(acetyloxy)benzoic acid, calcium phosphate and sodium hydrogen carbonate
- 2-acetoxybenzenecarboxylic acid
- 2-acetoxybenzenecarboxylic acid
- 2-acetoxybenzoic acid
- 2-acetoxybenzoic acid
- 8-hour bayer
- 8-hour bayer
- acetosalic acid
- acetosalic acid
- acetylphenylsalicylate
- acetylsalic acid
- acetylsalicylate
- acetylsalicylate
- acetylsalicylate
- acetyl salicylic acid
- acetyl salicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid
- acetylsalicylic acid lysinate
- acetylsalicylic acid lysinate
- acetylsalicylic acid lysinate
- acetylsalicylsäure
- acetylsalicylsäure
- acetylsalisylic acid
- acetylsalisylic acid
- acetylsalisylic acid
- acetylsalisylic acid
- acetylsalisylic acid
- acetylsalisylic acid
- acetylsalol
- acide 2-(acétyloxy)benzoïque
- acide 2-(acétyloxy)benzoïque
- acide acétylsalicylique
- acide acétylsalicylique
- ácido acetilsalicílico
- ácido acetilsalicílico
- acidum acetylsalicylicum
- acidum acetylsalicylicum
- aggrenox
- aggrenox
- alka rapid
- alka seltzer
- alka seltzer
- alka seltzer
- alka-seltzer
- anadin all night
- angettes 75
- asa
- asa
- asa
- aspegic
- aspirin
- aspirin
- aspirin
- aspirin
- aspirin
- aspirin
- aspirin
- aspirin anhydride
- aspirin calcium
- aspirin dl-lysine
- aspirin lysinate
- aspirin lysine
- aspirin lysine
- aspirin magnesium
- aspirin phenyl ester
- aspirin potassium
- aspirin sodium
- aspiron
- aspiron
- aspiryl-polylysine
- aspisol
- asprin
- asprin
- asprin dl-lysine
- aspro clr
- azetylsalizylsäure
- azetylsalizylsäure
- bayer extra strength
- clopidogrel / acetylsalicylic acid
- clopidogrel / acetylsalicylic acid
- clopidogrel aspirin
- coristina d
- danamep
- disprin cv
- disprin direct
- durlaza
- ecm
- ecm
- ecotrin
- ecotrin
- ecotrin
- enprin
- equi-prin
- flectadol
- gencardia
- high dose aspirin & vitamin d
- levius
- levius
- l-lysine, 2-(acetyloxy)benzoate (1:1)
- lysine acetylsalicylate
- lysine acetylsalicylate
- lysine acetylsalicylate
- lysine-acetylsalicylic acid
- lysine-aspirin
- max strgh aspro clr
- measurin
- measurin
- micropirin ec
- nu-seals 300
- nu-seals 600
- nu-seals 75
- nu-seals cardio 75
- o-acetoxybenzoic acid
- o-acetoxybenzoic acid
- o-acetylsalicylic acid
- o-acetylsalicylic acid
- o-carboxyphenyl acetate
- o-carboxyphenyl acetate
- pa32540
- pa32540
- paynocil
- phennin
- phenyl acetylsalicylate
- phenyl acetylsalicylate
- phenyl acetylsalicylate
- platet
- platet 300
- polopiryna
- polopiryna
- postmi 300
- postmi 75
- salicylic acid acetate
- salicylic acid acetate
- salicylic acid acetate
- sodium acetylsalicylate, sodium bicarbonate, and sodium citrate drug combination
- sodium acetylsalicylate -sodium bicarbonate - sodium citrate
- sodium acetylsalicylate, sodium bicarbonate, sodium citrate drug combination
- solusprin
- solusprin, monosalicylate, (dl-lys)-isomer
- solusprin, monosalicylate, (l-lys)-isomer
- venopirin
- vesipyrin
- yh14659
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07257198 | Phase 3 | Mar 1, 2026 | University of Montreal |
| NCT06774846 | Phase 3 | Feb 28, 2026 | University of Burgundy |
| NCT07243704 | Phase 3 | Jan 1, 2026 | All India Institute of Medical Sciences, Amrita Institute of Medical Sciences, Banaras Hindu University, Baptist Christian Hospital, Tezpur, India, Bharati Vidyapeeth University, Christian Medical College, Vellore, India, Government General Hospital Guntur, India, Government Medical College, India, Guru Gobind Singh Medical College, Indian Council of Medical Research, Kasturba Medical College, KG Hospital and Post Graduate Medical Institute Coimbatore, India, King George's Medical University, Narayana Hrudayalaya Limited, Rangaraya Medical College, SP Medical College, Bikaner, Sree Chitra Tirual Institute for Sciences and Technology, Kerela, St. Stephen's Hospital, Delhi, Tirunelveli Medical College, Tirunelveli, India |
| NCT07281547 | Phase 4 | Dec 12, 2025 | Mayo Clinic |
| NCT07213778 | Phase 3 | Dec 5, 2025 | Regeneron |
| NCT07228663 | Phase 3 | Dec 1, 2025 | Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network, McMaster University |
| NCT07275749 | Phase 3 | Dec 1, 2025 | Kafrelsheikh University |
| NCT07113158 | Phase 3 | Nov 30, 2025 | Assistance Publique - Hôpitaux de Paris |
| NCT07265466 | Phase 1 | Nov 17, 2025 | Onconic Therapeutics Inc. |
| NCT07041385 | N/A | Nov 1, 2025 | Shalamar Hospital |
| NCT07195812 | Phase 4 | Oct 31, 2025 | Nanchang University, Wenzhou Medical University, Zhejiang University |
| NCT07195149 | Phase 3 | Oct 31, 2025 | Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o., Government of Poland |
| NCT07240454 | N/A | Oct 15, 2025 | Capital Medical University, Tianjin Medical University, University of New South Wales |
| NCT07197463 | N/A | Oct 10, 2025 | Shandong University |
| NCT07205250 | Early Phase 1 (Phase 1) | Oct 8, 2025 | People's Liberation Army of China |
| NCT07052799 | Phase 3 | Oct 1, 2025 | Chinese University of Hong Kong |
| NCT07169513 | N/A | Oct 1, 2025 | University of London |
| NCT06916520 | Phase 4 | Sep 30, 2025 | University of Amsterdam |
| NCT07198529 | N/A | Sep 30, 2025 | Abbott, Korea University |
| NCT07180472 | Phase 4 | Sep 20, 2025 | Sichuan University |
Showing 20 of 1,272 trials
Page 1 / 64
Organizations
Research & Development (988)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 50 | 27 | 5 | 1899 |
| Capital Medical University | Academic/Hospital | 34 | 26 | 5 | 2008 |
| AstraZeneca | For profit | 33 | 19 | 5 | 2002 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 29 | 23 | 4 | 2006 |
| National Cancer Institute (NCI) | Government | 28 | 11 | 5 | 1992 |
| People's Liberation Army of China | Government | 26 | 16 | 5 | 2008 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 25 | 5 | 5 | 1974 |
| Boehringer Ingelheim | For profit | 24 | 20 | 5 | 1998 |
| Bristol-Myers Squibb | For profit | 24 | 10 | 5 | 1998 |
| Seoul National University | Academic/Hospital | 24 | 19 | 3 | 2005 |
| Harvard University | Academic/Hospital | 23 | 15 | 5 | 1981 |
| Jiao Tong University | Academic/Hospital | 22 | 16 | 4 | 2008 |
| McMaster University | Academic/Hospital | 22 | 10 | 4 | 1998 |
| University of Ulsan | Academic/Hospital | 22 | 15 | 3 | 2007 |
| National Institutes of Health (NIH) | Government | 17 | 1 | 5 | 2003 |
| University of London | Academic/Hospital | 16 | 9 | 3 | 1997 |
| Vanderbilt University | Academic/Hospital | 16 | 13 | 5 | 2001 |
| Yonsei University | Academic/Hospital | 16 | 14 | 2 | 2006 |
| Columbia University | Academic/Hospital | 15 | 9 | 4 | 1993 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 15 | 10 | 4 | 1974 |
988 organizations
Page 1 / 50
Marketing (91)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AAIPharma | For profit | MKTG | Sep 9, 1971 |
| AAIPharma | For profit | NDA2 | Sep 9, 1971 |
| AH Robins | For profit | MKTG | Apr 15, 1960 |
| AH Robins | For profit | NDA2 | Apr 15, 1960 |
| Abbott | For profit | MKTG | Dec 14, 1983 |
| Actavis | For profit | MKTG | Jul 25, 1979 |
| Actavis | For profit | SYN | Mar 22, 2011 |
| Allergan | For profit | NDA2 | May 4, 1976 |
| Allergan | For profit | MKTG | May 4, 1976 |
| Alta Pharma | For profit | MKTG | Sep 23, 1975 |
| Amneal Pharmaceuticals | For profit | MKTG | Mar 8, 2016 |
| Ani Pharmaceuticals | For profit | MKTG | Jan 18, 2017 |
| Ani Pharmaceuticals | For profit | SYN | Feb 27, 1998 |
| Aurobindo Pharma | For profit | MKTG | Feb 2, 2022 |
| Barr Laboratories | For profit | MKTG | Aug 14, 2009 |
| Bausch Health Companies | For profit | NDA2 | Mar 4, 1964 |
| Bayer | For profit | NDA | Jun 25, 1965 |
| Boehringer Ingelheim | For profit | MKTG | Nov 22, 1999 |
| Boehringer Ingelheim | For profit | NDA2 | Nov 22, 1999 |
| Bristol-Myers Squibb | For profit | MKTG | Jun 24, 2003 |
| Bristol-Myers Squibb | For profit | NDA2 | Jun 24, 2003 |
| Chartwell Pharmaceuticals | For profit | MKTG | Mar 20, 2019 |
| Chartwell Pharmaceuticals | For profit | SYN | Mar 31, 1989 |
| Dr. Reddy's Laboratories | For profit | MKTG | Oct 10, 2018 |
| Dr. Reddy's Laboratories | For profit | SYN | Oct 10, 2018 |
| Dr. Reddy's Laboratories | For profit | SYN | Mar 16, 2011 |
| Endo Pharmaceuticals | For profit | MKTG | Apr 12, 1950 |
| Endo Pharmaceuticals | For profit | NDA2 | Apr 12, 1950 |
| Epic Pharma Llc | For profit | MKTG | Jul 16, 2020 |
| Espero BioPharma | For profit | NDA2 | Sep 4, 2015 |
| Esteve Labs | For profit | MKTG | Sep 22, 2016 |
| Fosun | For profit | MKTG | Jul 30, 1980 |
| Galt Pharmaceuticals | For profit | MKTG | May 29, 1998 |
| Genus Oncology, LLC | For profit | MKTG | Sep 14, 2016 |
| Genus Oncology, LLC | For profit | NDA2 | Sep 14, 2016 |
| GlaxoSmithKline | For profit | MKTG | Jan 14, 1998 |
| GlaxoSmithKline | For profit | NDA2 | Jan 14, 1998 |
| Glenmark Pharmaceuticals | For profit | MKTG | May 24, 2019 |
| Granules India | For profit | MKTG | Feb 23, 2021 |
| Halsey | For profit | MKTG | Jul 1, 1982 |
| Heritage Pharma | For profit | MKTG | Mar 31, 1989 |
| Hikma | For profit | MKTG | Jun 5, 1979 |
| Ingenus Pharmaceuticals | For profit | MKTG | Jan 7, 2010 |
| Ivax | For profit | MKTG | — |
| Jerome Stevens Pharmaceuticals | For profit | MKTG | Jan 31, 1995 |
| Johnson and Johnson | For profit | MKTG | Feb 12, 1986 |
| LGM Pharma | For profit | MKTG | Nov 30, 2001 |
| Lannett Company, Inc. | For profit | MKTG | Dec 28, 1981 |
| Lannett Company, Inc. | For profit | SYN | Mar 20, 2019 |
| Mayne Pharma | For profit | MKTG | Mar 16, 2011 |
| McNeil | For profit | MKTG | Feb 12, 1986 |
| Meda Pharmaceuticals | For profit | MKTG | Sep 12, 1960 |
| Meda Pharmaceuticals | For profit | NDA2 | Sep 12, 1960 |
| Medicis | For profit | MKTG | Mar 4, 1964 |
| Medpointe | For profit | MKTG | Jul 31, 1978 |
| Micro Labs Ltd India | For profit | MKTG | Aug 11, 2021 |
| Mikart | For profit | MKTG | Oct 26, 1990 |
| Nexgen Pharma, Inc | For profit | MKTG | Nov 30, 2001 |
| Nostrum Laboratories | For profit | MKTG | Jun 13, 2007 |
| Novartis | For profit | MKTG | Apr 16, 1996 |
| Novast Labs | For profit | MKTG | Jan 7, 2010 |
| Oxford Pharmaceuticals | For profit | MKTG | Dec 10, 1997 |
| PLx Pharma | For profit | NDA2 | Jan 14, 2013 |
| Par Pharmaceuticals | For profit | MKTG | Nov 4, 1988 |
| Par Pharmaceuticals | For profit | SYN | Jan 18, 2017 |
| Perrigo | For profit | MKTG | Nov 26, 2001 |
| Pharmaceutics International, Inc. | For profit | MKTG | Sep 22, 2016 |
| Puracap Pharmaceutical | For profit | MKTG | Apr 30, 1980 |
| Quantum Pharmaceutical | For profit | MKTG | — |
| R.P. Scherer | For profit | MKTG | May 10, 1978 |
| Roxane Laboratories | For profit | MKTG | Jun 4, 1982 |
| Sandoz | For profit | MKTG | Dec 22, 1970 |
| Sandoz | For profit | SYN | Jan 18, 2017 |
| Sanofi-Aventis | For profit | MKTG | Nov 12, 1975 |
| Sanofi-Aventis | For profit | NDA2 | Nov 12, 1975 |
| Savage Labs | For profit | MKTG | — |
| Schwarz Pharma | For profit | MKTG | Jan 25, 1988 |
| SmithKline Beecham | For profit | NDA2 | Oct 26, 1990 |
| Strides Pharma Science | For profit | MKTG | Sep 22, 2016 |
| Sun Pharmaceuticals | For profit | MKTG | Aug 21, 2018 |
| Sun Pharmaceuticals | For profit | SYN | Jul 7, 1958 |
| Sun Pharmaceuticals | For profit | SYN | Aug 21, 2018 |
| Sun Pharmaceuticals | For profit | NDA2 | Jul 7, 1958 |
| Teva | For profit | SYN | Mar 29, 1985 |
| Teva | For profit | SYN | Jan 20, 2023 |
| Teva | For profit | MKTG | Apr 14, 1978 |
| Vintage | For profit | MKTG | Mar 5, 1999 |
| Watson Pharmaceuticals | For profit | MKTG | Aug 21, 1978 |
| Xanodyne Pharmaceuticals | For profit | MKTG | Nov 12, 1957 |
| Xanodyne Pharmaceuticals | For profit | NDA2 | Nov 12, 1957 |
| Zydus Discovery DMCC | For profit | MKTG | Aug 29, 2017 |